XML 78 R65.htm IDEA: XBRL DOCUMENT
v3.25.1

Note 15 - Commitments and Contingencies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands |  |  |  |  |  |  | 1 Months Ended | 12 Months Ended |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Aug. 31, 2024 | Aug. 30, 2024 | Sep. 13, 2022 | Oct. 28, 2021 | Jun. 15, 2021 | Mar. 26, 2020 | Dec. 31, 2024 | Aug. 31, 2024 | Mar. 31, 2024 | Nov. 30, 2023 | Oct. 31, 2023 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Nov. 30, 2024 | Sep. 30, 2024 | Mar. 14, 2023 | Nov. 30, 2022 | Dec. 31, 2021 | Mar. 27, 2020
Stock Issued During Period, Value, New Issues |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 7,000 |  |  |  |  |  |  |  |
Share Price (in dollars per share) |  |  |  |  |  |  | $ 3.22 |  |  |  |  |  |  | $ 3.22 | $ 2.32 | $ 2.32 |  | $ 6 |  |  |  |
Research and Development Expense, Total |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,255 | $ 3,322 | $ 3,996 |  |  |  |  |  |
Cost of Goods and Services Sold |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,600 | 10,581 | 6,933 |  |  |  |  |  |
Common Stock [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock Issued During Period, Shares, New Issues (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 583,334 |  |  |  |  |  |  |  |
Stock Issued During Period, Value, New Issues |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1 |  |  |  |  |  |  |  |
Share Price (in dollars per share) |  |  |  |  |  | $ 3.33 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of Goods and Services Sold |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 270 | 1,000 | $ 1,640 |  |  |  |  |  |
Carglumic Acid Tablets [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Marketing Rights |  |  |  | $ 3,250 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment, Allocation of Profits, Percentage |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Betaine Anhydrous [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Marketing Rights |  |  | $ 2,000 |  |  |  |  |  |  | $ 125 |  |  |  |  |  |  |  |  |  |  |  |
Commitment, Allocation of Profits, Percentage |  |  | 65.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Betaine Anhydrous [Member] | Obligation Based on Commercial Success [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitment |  |  | $ 1,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
FDA-Approved ANDA For Nitisinone [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Marketing Rights |  |  |  |  |  |  |  |  |  |  | $ 150 |  |  |  |  |  |  |  |  |  |  |
Commitment, Allocation of Profits, Percentage |  |  |  |  |  |  |  |  |  |  | 80.00% |  |  |  |  |  |  |  |  |  |  |
FDA-Approved ANDA For Nitisinone [Member] | Obligation Based on Acceptance of FDA of NDA for product [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Marketing Rights |  |  |  |  |  |  |  |  |  |  | $ 500 |  |  |  |  |  |  |  |  |  |  |
PKU GoLike [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitment |  |  |  |  |  |  |  |  | $ 2,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment, Milestone Fee |  |  |  |  |  |  |  |  | $ 500 |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty on Net Sales of Products, Percent |  |  |  |  |  |  |  |  | 30.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Marketing Rights |  |  |  |  |  |  |  |  | $ 2,200 |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment, Milestone One Revenue |  |  |  |  |  |  |  |  | 4,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment, Milestone Two Revenue |  |  |  |  |  |  |  |  | 8,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment, Milestone Three Revenue |  |  |  |  |  |  |  |  | 15,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment, Milestone Four Revenue |  |  |  |  |  |  |  |  | $ 20,000 |  |  |  |  |  |  |  |  |  |  |  |  |
GALZIN [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Marketing Rights |  |  |  |  |  |  | $ 7,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalties, Percentage of Net Sales, |  |  |  |  |  |  | 10.00% |  |  |  |  |  |  | 10.00% |  |  |  |  |  |  |  |
GALZIN [Member] | Inventories [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Marketing Rights |  |  |  |  |  |  | $ 200 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increlex [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitment |  |  |  |  |  |  | 2,500 |  |  |  |  |  |  | $ 2,500 |  |  |  |  |  |  |  |
Payments to Acquire Marketing Rights |  |  |  |  |  |  | 22,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Inventory |  |  |  |  |  |  | $ 7,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Azurity Pharmaceuticals, Inc. (“Azurity”) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, Additional Based on Event and Sales-based Milestones Achievements |  |  |  |  |  |  |  |  |  |  |  | $ 5,500 |  |  |  |  |  |  |  |  |  |
Azurity Pharmaceuticals, Inc. (“Azurity”) [Member] | Milestone Method [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 27,500 |  |  |  |  |  |  |  |
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on Successful Manufacturing of Registration Batches [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 450 |  |  |
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on Acceptance of FDA of NDA for product [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 200 |  |  |
Royalties, Percentage of Net Sales, |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12.50% |  |  |
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on First Commercial Sale of Product [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 250 |  |  |
Royalties, Percentage of Net Sales, |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 17.00% |  |  |
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Topiramate (fka ET-101) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accounts Receivable, after Allowance for Credit Loss, Total |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000 |
Liqmeds Worldwide Limited (“LMW”) [Member] | Licensing and Supply Agreement (the “Agreement”) [Member] | Obligation Based on Issuance of Orange-book Listed Patent [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 650 |  |
Diurnal Limited [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate Value of Licensing Milestone Included in Research and Development Expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000 |  |  |  |  |  |  |
Diurnal Limited [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | Common Stock [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock Issued During Period, Shares, New Issues (in shares) |  |  |  |  |  | 379,474 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock Issued During Period, Value, New Issues |  |  |  |  |  | $ 1,264 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Diurnal Limited [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | Obligation Based on Exclusivity Status from FDA [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,500
Diurnal Limited [Member] | License [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment, Milestone Fee |  |  |  |  |  | $ 3,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Crossject [Member] | U.S. and Canadian rights to Crossject S.A.’s [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Expense, Total |  |  |  |  | $ 500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty on Net Sales of Products, Percent |  |  |  |  | 10.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Crossject [Member] | U.S. and Canadian rights to Crossject S.A.’s [Member] | Obligation Based on Development Milestones [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitment |  |  |  |  | $ 3,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Crossject [Member] | U.S. and Canadian rights to Crossject S.A.’s [Member] | Obligation Based on Commercial Success [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitment |  |  |  |  | $ 6,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Dr. Reddy’s [Member] | License [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000 |  |  |  |  |  |  |  |  |
Sintetica [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of Goods and Services Sold |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 812 |  |  |  |  |  |  |
Selenix [Member] | DS-200 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, Additional Based on Event and Sales-based Milestones Achievements |  |  |  |  |  |  |  | $ 6,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment, Allocation of Profits, Percentage | 45.00% | 50.00% |  |  |  |  |  | 45.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds From Up-front Payment |  |  |  |  |  |  |  | $ 500 |  |  |  |  |  |  |  |  |  |  |  |  |  |
AMMTeK [Member] | Amglidia [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalties, Percentage of Net Sales, |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 14.00% |  |  |  |  |
AMMTeK [Member] | Amglidia [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,350 |  |  |  |  |
AMMTeK [Member] | Amglidia [Member] | Receipt of FDA Minutes [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 500 |  |  |  |  |
AMMTeK [Member] | Amglidia [Member] | NDA Acceptance for Review by FDA [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 550 |  |  |  |  |
AMMTeK [Member] | Amglidia [Member] | NDA Approval by the FDA and First Commercial Sale [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,300 |  |  |  |  |

X
- Definition Aggregate value of licensing milestone amount included in research and development expense. + References No definition available. + Details
Name: | eton_AggregateValueOfLicensingMilestoneIncludedInResearchAndDevelopmentExpense
Namespace Prefix: | eton_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Information on the allocation of profits as a percentage. + References No definition available. + Details
Name: | eton_CommitmentAllocationOfProfitsPercentage
Namespace Prefix: | eton_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Information on milestone fee. + References No definition available. + Details
Name: | eton_CommitmentMilestoneFee
Namespace Prefix: | eton_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue for milestone four. + References No definition available. + Details
Name: | eton_CommitmentMilestoneFourRevenue
Namespace Prefix: | eton_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue for milestone one. + References No definition available. + Details
Name: | eton_CommitmentMilestoneOneRevenue
Namespace Prefix: | eton_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue for milestone three. + References No definition available. + Details
Name: | eton_CommitmentMilestoneThreeRevenue
Namespace Prefix: | eton_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue for milestone two. + References No definition available. + Details
Name: | eton_CommitmentMilestoneTwoRevenue
Namespace Prefix: | eton_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash outflow to acquire inventory. + References No definition available. + Details
Name: | eton_PaymentsToAcquireInventory
Namespace Prefix: | eton_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow from amounts paid for marketing rights. + References No definition available. + Details
Name: | eton_PaymentsToAcquireMarketingRights
Namespace Prefix: | eton_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In relation to proceeds from payments received upfront. + References No definition available. + Details
Name: | eton_ProceedsFromUpfrontPayment
Namespace Prefix: | eton_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Information on additional revenue based on event-based and sales-based milestones achievements. + References No definition available. + Details
Name: | eton_RevenueAdditionalBasedOnEventAndSalesbasedMilestonesAchievements
Namespace Prefix: | eton_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents percentage of net sales related to royalties. + References No definition available. + Details
Name: | eton_RoyaltiesPercentageOfNetSales
Namespace Prefix: | eton_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Information pertaining to the royalty on the net sales of all products as a percentage. + References No definition available. + Details
Name: | eton_RoyaltyOnNetSalesOfProductsPercent
Namespace Prefix: | eton_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details
Name: | us-gaap_AccountsReceivableNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details
Name: | us-gaap_OtherCommitment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1 Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=eton_CarglumicAcidTabletsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=eton_BetaineAnhydrousMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=eton_ObligationBasedOnCommercialSuccessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=eton_FdaapprovedAndaForNitisinoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=eton_ObligationBasedOnAcceptanceOfFdaOfNdaForProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=eton_PkuGolikeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=eton_GalzinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_InventoriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=eton_IncrelexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=eton_AzurityPharmaceuticalsIncAzurityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=eton_MilestoneMethodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=eton_TulexPharmaceuticalsIncTulexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=eton_ObligationBasedOnSuccessfulManufacturingOfRegistrationBatchesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=eton_ObligationBasedOnFirstCommercialSaleOfProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=eton_TopiramateFkaET101Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=eton_LiqmedsWorldwideLimitedLMWMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=eton_LicensingAndSupplyAgreementTheAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=eton_ObligationBasedOnIssuanceOfOrangebookListedPatentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=eton_DiurnalLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=eton_ExclusiveLicensingAndSupplyAgreementTheAlkindiLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=eton_ObligationBasedOnExclusivityStatusFromFdaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=eton_CrossjectMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=eton_USAndCanadianRightsToCrossjectSASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=eton_ObligationBasedOnDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=eton_DrReddysMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=eton_SinteticaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=eton_SelenixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=eton_Ds200Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=eton_AmmtekMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=eton_AmglidiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=eton_ReceiptOfFdaMinutesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=eton_NdaAcceptanceForReviewByFdaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=eton_NdaApprovalByTheFdaAndFirstCommercialSaleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |